Eluxadoline

mu-Opioid Receptor Agonist — ALIMENTARY TRACT AND METABOLISM

Key facts

Eluxadoline is an onp drug in the mu-Opioid Receptor Agonist class catalogued in DrugCentral. It was first approved by the FDA in 2015. Its mechanism of action is classified as Opioid mu-Receptor Agonists. DrugCentral lists 6 molecular targets, including Oprm1, Oprd1 and OPRD1. Recorded indications include Irritable bowel syndrome with diarrhea.

• Approval status: onp (first approved 2015 by the FDA).
• Drug class: mu-Opioid Receptor Agonist.
• Mechanism of action: Opioid mu-Receptor Agonists.
• Molecular targets: Oprm1, Oprd1, OPRD1 and OPRM1 (6 listed in DrugCentral).
• Indications: Irritable bowel syndrome with diarrhea.
• ATC code: A07DA06 (Antipropulsives).
• Molecular formula: C32H35N5O5; molecular weight 569.66 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Irritable bowel syndrome with diarrhea

Mechanism & targets

• Mechanism of action (MoA): Opioid mu-Receptor Agonists
• Established pharmacologic class: mu-Opioid Receptor Agonist

Molecular targets (6)

Target	Gene	Action	Activity
Mu-type opioid receptor	Oprm1	unknown	Ki 9.05
Delta-type opioid receptor	Oprd1	unknown	Ki 8.89
Delta-type opioid receptor	OPRD1	antagonist	Ki 8.89
Mu-type opioid receptor	OPRM1	agonist	Ki 8.77
Kappa-type opioid receptor	OPRK1	agonist	Ki 7.26
Kappa-type opioid receptor	OPRK1	agonist	Ki 7.26

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2016-09-19	EMA	—	Allergan Pharmaceuticals International Limited
2015-05-27	FDA	—	FURIEX PHARMA INC

ATC classification

ATC code	Therapeutic hierarchy
A07DA06	ALIMENTARY TRACT AND METABOLISM › ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS › ANTIPROPULSIVES › Antipropulsives

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Pancreatitis	138.3
Abdominal pain	99.6
Contraindicated product prescribed	89.1
Sphincter of Oddi dysfunction	88.7
Constipation	62.0
Abdominal pain upper	50.5
Diarrhoea	48.4
Pancreatitis acute	44.1
Off label use	31.4

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Eluxadoline is on its molecule page.

• Molecular formula: C₃₂H₃₅N₅O₅
• Molecular weight: 569.66 g/mol
• CAS number: 864821-90-9
• InChIKey: QFNHIDANIVGXPE-FNZWTVRRSA-N
• PubChem CID: 11250029

COC1=CC=C(CN([C@@H](C)C2=NC(=CN2)C2=CC=CC=C2)C(=O)[C@@H](N)CC2=C(C)C=C(C=C2C)C(N)=O)C=C1C(O)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Eluxadoline used for?

DrugCentral lists the following indications for Eluxadoline: Irritable bowel syndrome with diarrhea.

How does Eluxadoline work?

Eluxadoline is classified as Opioid mu-Receptor Agonists; its molecular targets in DrugCentral include Oprm1, Oprd1, OPRD1 (antagonist) and OPRM1 (agonist).

When was Eluxadoline first approved?

Eluxadoline was first approved by the FDA in 2015.

What drug class does Eluxadoline belong to?

Eluxadoline is in the mu-Opioid Receptor Agonist class.

What is the chemical formula of Eluxadoline?

Eluxadoline has the molecular formula C32H35N5O5 and a molecular weight of 569.66 g/mol.

Sources

• DrugCentral drug card 5001 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL2159122 — compound record and bioactivity
• PubChem CID 11250029 — chemical identifiers
• DrugBank DB09272 — drug record
• FDA UNII 45TPJ4MBQ1 — substance identity
• DailyMed: FDA labels for Eluxadoline — current prescribing information (label search)
• UniProt P41143 (OPRD1) — target protein
• UniProt P35372 (OPRM1) — target protein
• UniProt P41145 (OPRK1) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.